Inactive Instrument

Neuralstem, Inc. Stock Nasdaq

US64127R3021

End-of-day quote Nasdaq
- ^USD	-

08-10	Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-23	Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target	MT

Latest news : Neuralstem, Inc.

08-10	Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-23	Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target	MT
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Small Cap Comp Growth Benchmark	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2500 Growth Benchmark	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Index	CI
06-29	Palisade Bio Receives FDA Clearance Of IND For PALI-2108 And Plans To Initiate Global Phase 2 ASCENTRA-UC Study In Ulcerative Colitis	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Value Benchmark	CI
06-29	Palisade Bio Shares Rise After FDA Clears PALI-2108 for Phase 2 Trial	DJ
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Microcap Value Benchmark Index	CI
06-29	Palisade Bio Gets FDA IND Clearance for Phase 2 PALI-2108 UC Study	MT
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Microcap Growth Benchmark Index	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Growth Benchmark	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 3000E Growth Benchmark	CI

More news

Analysts' recommendations: Neuralstem, Inc.

07-23	Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target	MT
03-26	HC Wainwright Initiates Coverage on Palisade Bio With Buy Rating, $7 Price Target	MT
02-25	Stifel Initiates Palisade Bio at Buy With $5 Price Target	MT
01-09	B. Riley Initiates Palisade Bio at Buy With $7 Price Target	MT
23-11-17	Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $1.50	MT

More recommendations

Press Releases: Neuralstem, Inc.

08-10	Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development	AQ
07-10	Palisade Bio to Participate in the Leerink Partners Therapeutics Forum	AQ
06-29	Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis	AQ
06-11	Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors	AQ
06-10	Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium	AQ

More press releases

News in other languages: Neuralstem, Inc.

24-01-29	MÄRKTE USA/Fester - Neue Rekordhochs dank sinkender Anleihezinsen
24-01-29	LATE BRIEFING - Unternehmen und Märkte
24-01-29	MÄRKTE USA/Kaum verändert - Vor Fed-Entscheid dominiert Zurückhaltung
24-01-29	MÄRKTE USA/Wall Street startet wenig verändert in Fed-Woche
24-01-29	MÄRKTE USA/Wall Street wenig verändert erwartet

More news

Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.

Employees

Sector

More about the company

Market Cap	375M 324M 304M 277M 520M 35.83B 529M 3.56B 1.39B 17.94B 1.41B 1.38B 59.62B	P/E 2026 *	-9.61x	P/E 2027 *	-7.85x
Enterprise Value	277M 239M 225M 204M 384M 26.49B 391M 2.63B 1.03B 13.26B 1.04B 1.02B 44.08B	EV / Sales 2026 *	969x	EV / Sales 2027 *	-
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

	2026 *	2027 *
Net sales	286K 247K 232K 211K 396K 27.32M 403K 2.72M 1.06M 13.68M 1.07M 1.05M 45.46M	-
Net income	-47.56M -41.08M -38.6M -35.11M -66M -4.55B -67.09M -452M -177M -2.28B -179M -175M -7.57B	-62.57M -54.04M -50.78M -46.18M -86.83M -5.98B -88.26M -595M -233M -3B -235M -230M -9.96B
Net Debt	-97.7M -84.38M -79.29M -72.11M -136M -9.34B -138M -929M -363M -4.68B -367M -359M -15.55B	-335M -289M -272M -247M -464M -32B -472M -3.18B -1.24B -16.03B -1.26B -1.23B -53.26B

Neuralstem, Inc. Stock Nasdaq

Stocks

US64127R3021

Valuation: Neuralstem, Inc.

Latest news : Neuralstem, Inc.

Analysts' recommendations: Neuralstem, Inc.

Press Releases: Neuralstem, Inc.

News in other languages: Neuralstem, Inc.

Financials

Company Profile